Joseph P. McEvoy, MD

Patients Living With Tardive Dyskinesia

January 25, 2018

A series of 6 brief educational videos featuring expert insight and comments by actual patients and their family members helps people understand the risk factors for TD, recognize the...

Joseph P. McEvoy, Andrew A. Nierenberg

Original Research

Therapeutic Durability of Aripiprazole Lauroxil

September 19, 2017

Injectable antipsychotics can help address the problem of nonadherence, which can lead to relapse. This study looks at the efficacy of the injectable antipsychotic aripiprazole lauroxil in achieving and...

Joseph P. McEvoy, Robert Risinger, Serhiy Mykhnyak, et al

Original Research

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

January 15, 2013

Joseph P. McEvoy, Leslie Citrome, David Hernandez, et al

Original Research

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

March 6, 2012

Nancy H. Covell, Joseph P. McEvoy, Nina R. Schooler, et al

Original Research

Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia

September 21, 2010

Donald E. Addington, Somaia Mohamed, Robert A. Rosenheck, et al

Original Research

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

August 10, 2010

Stanley N. Caroff, Vicki G. Davis, Del D. Miller, et al

Article

Functional Outcomes in Schizophrenia

May 31, 2008

Joseph P. McEvoy

Original Research

Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder: A Randomized, Double-Blind, Flexible-Dose, Multicenter Study

January 15, 2008

Diana O. Perkins, Hongbin Gu, Peter J. Weiden, et al

Article

The Costs of Schizophrenia.

December 14, 2007

Joseph P. McEvoy

Original Research

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

November 15, 2007

Troy A. Moore, Robert W. Buchanan, Peter F. Buckley, et al

Article

Risks Versus Benefits of Different Types of Long-Acting Injectable Antipsychotics.

May 15, 2006

Joseph P. McEvoy

Original Research

Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia

April 1, 2004

Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, et al

Patients Living With Tardive Dyskinesia

Therapeutic Durability of Aripiprazole Lauroxil

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

Functional Outcomes in Schizophrenia

Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder: A Randomized, Double-Blind, Flexible-Dose, Multicenter Study

The Costs of Schizophrenia.

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

Risks Versus Benefits of Different Types of Long-Acting Injectable Antipsychotics.

Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia

ELSEWHERE:

FOLLOW US:

Joseph P. McEvoy, MD

Patients Living With Tardive Dyskinesia

Therapeutic Durability of Aripiprazole Lauroxil

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

Functional Outcomes in Schizophrenia

Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder: A Randomized, Double-Blind, Flexible-Dose, Multicenter Study

The Costs of Schizophrenia.

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

Risks Versus Benefits of Different Types of Long-Acting Injectable Antipsychotics.

Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles